secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-129170
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Therapeutics amends bylaws to designate federal courts for securities claims
--------------------------------------------------------------------------------

- Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.
- Federal district courts designated exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934.
- Amendment effective immediately; company may consent to alternative forum in writing.
- Change made in response to recent amendments to Delaware General Corporation Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/0001193125-26-129170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526129170/d122194d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-129170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer